Japan Tobacco (JAPAF) 34.4900 $JAPAF
3 Reasons Reynolds American's Stock Price Could Fall
Ted Cooper, The Motley Fool - Motley Fool - Mon Sep 08, 7:26PM CDT
Reynolds American has been on the rise since posting solid second-quarter earnings. The Q2 report showed market share gains for each of its key brands, and management raised the low end of full-year earnings0per-share guidance from $3.30 to $3.35....
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
World Cigarettes Report 2014 - 1st Edition Covering 66 Countries
M2 - Thu Aug 14, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v8k4z/world_cigarettes) has announced the addition of the "World Cigarettes 1 2013" report to their offering. World Cigarettes Report 2014 - 1st Edition is a new report that focuses on the extent to which the global cigarette market has evolved during the last twelve years in line with changing smoking habits, the competitive environment and economic developments, as well as analyzing the implications market realignments have had on top multinational companies. Key Highlights - The USA is the world's second largest cigarette market, but is also in long-term decline. Market volumes, based on shipment data, fell by just over 2% to 286.5 billion pieces in 2012, 45% below 1990 levels. - China is by far the largest cigarette market in the world with domestic consumption estimated at 2,520.7 billion pieces in 2013 putting the market 55.3% up on 1990 levels, with most of the growth having occurred since 2000 - France remains one of the largest cigarette markets in Western Europe, despite a substantial contraction in market volume since 1990, with annual duty paid volume declining by a further 4.9% to 51.46 billion pieces in 2012, which compares with 82.51 billion pieces in 2000 and a 46.3% fall since 1990. Synopsis - World Cigarettes Report 2014 - 1st Edition is a qualitative report providing extensive and highly detailed consumption data on the Cigarette industry in 66 countries. - This report is aimed at companies operating in the Cigarette industry and for new companies considering entry into Cigarette industry. - This report provides detailed data of the manufacturers operating in the Cigarette industry in the 66 countries across the five regions. - This report also provides market size of the Cigarette industry in the 66 countries along with other data relating to the regulations, retail price, smoking population, production & trade and forecast data. Companies Mentioned - Philip Morris France SAS - Seita-Groupe Imperial Tobacco/Imperial Tobacco France - Imperial Tobacco Ltd - Gallaher Group Ltd - BAT (UK) Limited - Shanghai Tobacco Group - Hongta Group - Hunan Provincial China Tobacco Industry Corp - Hongyun Honghe Tobacco Group - Zhejiang Provincial China Tobacco Industry Corp - ITC Ltd - Godfrey Phillips India Ltd - VST Industries Ltd - Golden Tobacco Ltd - Philip Morris Polska SA - British American Tobacco Polska SA - Imperial Tobacco Polska SA - JTI Polska Sp. z.o.o (JTI Poland) - Japan Tobacco International Russia - Philip Morris Russia - British American Tobacco Russia - Imperial Tobacco Sales and Marketing LLC - OJSC Donskoy Tabak - Imperial Tobacco Maroc - British American Tobacco (South Africa) Ltd - Philip Morris Sabanci Sigara ve T?t?nc?l?k Sanayi ve Ticaret AS (PHILSA) - Japan Tobacco T?t?n Sanayi AS - British American Tobacco Turkey. For more information visit http://www.researchandmarkets.com/research/5v...cigarettes
One in ten cigarettes consumed in the EU in 2013 were illegal
M2 - Tue Jun 24, 9:05AM CDT
New KPMG study for British American Tobacco, Imperial Tobacco, Japan Tobacco International and Philip Morris International
One in Ten Cigarettes Consumed in the EU in 2013 Were Illegal; Dramatic Rise in Consumption of 'Illicit Whites'
Business Wire - Tue Jun 24, 6:00AM CDT
One in every ten cigarettes consumed in the European Union in 2013 were illicit, 33% of which were "illicit whites", an emerging type of illegal, branded cigarettes manufactured for the sole purpose of being smuggled, according to a KPMG study published today. At these levels, EU governments lost approximately EUR10.9 billion to the illegal market.
How Philip Morris, Altria and Lorillard Are Upping Their Market Share
Furqan Asad, Suhail, The Motley Fool - Motley Fool - Fri Jun 13, 10:25AM CDT
The Tobacco companies, including Philip Morris (NYSE: PM) , Altria (NYSE: MO) and Lorillard (NYSE: LO) , are facing volume growth challenges because of regulations and increasing health awareness among consumers. Tobacco companies have been...
Orange Business Services to Unify Communications and Develop Collaboration between 20,000 Users for JTI
Business Wire - Mon Mar 31, 3:00AM CDT
Orange Business Services has been chosen by JTI (Japan Tobacco International) to transform its digital working environment by moving its existing communications landscape to a fully managed unified communications solution based on Microsoft Lync(R) 2013.
Analyzing the Global Tobacco Industry 2014
M2 - Thu Mar 27, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ncfrq/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Major players in the industry are analyzed through a company overview, business segment analysis, financial analysis, and a SWOT analysis. With tobacco being one of the most commonly used addictive substances in the world, the industry will continue to grow in the coming years, though the growth is going to be faced with many challenges as countries put in place stringent laws to combat the health effects of consuming tobacco. Aruvians Rsearch's analysis of the global tobacco industry is a comprehensive analysis of the industry. Companies Mentioned - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor Visit http://www.researchandmarkets.com/research/4n...lyzing_the
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"
, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Reasons Reynolds American's Stock Price Could Fall
Ted Cooper, The Motley Fool - Motley Fool - Mon Sep 08, 7:26PM CDT
Reynolds American has been on the rise since posting solid second-quarter earnings. The Q2 report showed market share gains for each of its key brands, and management raised the low end of full-year earnings0per-share guidance from $3.30 to $3.35....
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
World Cigarettes Report 2014 - 1st Edition Covering 66 Countries
M2 - Thu Aug 14, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v8k4z/world_cigarettes) has announced the addition of the "World Cigarettes 1 2013" report to their offering. World Cigarettes Report 2014 - 1st Edition is a new report that focuses on the extent to which the global cigarette market has evolved during the last twelve years in line with changing smoking habits, the competitive environment and economic developments, as well as analyzing the implications market realignments have had on top multinational companies. Key Highlights - The USA is the world's second largest cigarette market, but is also in long-term decline. Market volumes, based on shipment data, fell by just over 2% to 286.5 billion pieces in 2012, 45% below 1990 levels. - China is by far the largest cigarette market in the world with domestic consumption estimated at 2,520.7 billion pieces in 2013 putting the market 55.3% up on 1990 levels, with most of the growth having occurred since 2000 - France remains one of the largest cigarette markets in Western Europe, despite a substantial contraction in market volume since 1990, with annual duty paid volume declining by a further 4.9% to 51.46 billion pieces in 2012, which compares with 82.51 billion pieces in 2000 and a 46.3% fall since 1990. Synopsis - World Cigarettes Report 2014 - 1st Edition is a qualitative report providing extensive and highly detailed consumption data on the Cigarette industry in 66 countries. - This report is aimed at companies operating in the Cigarette industry and for new companies considering entry into Cigarette industry. - This report provides detailed data of the manufacturers operating in the Cigarette industry in the 66 countries across the five regions. - This report also provides market size of the Cigarette industry in the 66 countries along with other data relating to the regulations, retail price, smoking population, production & trade and forecast data. Companies Mentioned - Philip Morris France SAS - Seita-Groupe Imperial Tobacco/Imperial Tobacco France - Imperial Tobacco Ltd - Gallaher Group Ltd - BAT (UK) Limited - Shanghai Tobacco Group - Hongta Group - Hunan Provincial China Tobacco Industry Corp - Hongyun Honghe Tobacco Group - Zhejiang Provincial China Tobacco Industry Corp - ITC Ltd - Godfrey Phillips India Ltd - VST Industries Ltd - Golden Tobacco Ltd - Philip Morris Polska SA - British American Tobacco Polska SA - Imperial Tobacco Polska SA - JTI Polska Sp. z.o.o (JTI Poland) - Japan Tobacco International Russia - Philip Morris Russia - British American Tobacco Russia - Imperial Tobacco Sales and Marketing LLC - OJSC Donskoy Tabak - Imperial Tobacco Maroc - British American Tobacco (South Africa) Ltd - Philip Morris Sabanci Sigara ve T?t?nc?l?k Sanayi ve Ticaret AS (PHILSA) - Japan Tobacco T?t?n Sanayi AS - British American Tobacco Turkey. For more information visit http://www.researchandmarkets.com/research/5v...cigarettes
One in ten cigarettes consumed in the EU in 2013 were illegal
M2 - Tue Jun 24, 9:05AM CDT
New KPMG study for British American Tobacco, Imperial Tobacco, Japan Tobacco International and Philip Morris International
One in Ten Cigarettes Consumed in the EU in 2013 Were Illegal; Dramatic Rise in Consumption of 'Illicit Whites'
Business Wire - Tue Jun 24, 6:00AM CDT
One in every ten cigarettes consumed in the European Union in 2013 were illicit, 33% of which were "illicit whites", an emerging type of illegal, branded cigarettes manufactured for the sole purpose of being smuggled, according to a KPMG study published today. At these levels, EU governments lost approximately EUR10.9 billion to the illegal market.
How Philip Morris, Altria and Lorillard Are Upping Their Market Share
Furqan Asad, Suhail, The Motley Fool - Motley Fool - Fri Jun 13, 10:25AM CDT
The Tobacco companies, including Philip Morris (NYSE: PM) , Altria (NYSE: MO) and Lorillard (NYSE: LO) , are facing volume growth challenges because of regulations and increasing health awareness among consumers. Tobacco companies have been...
Orange Business Services to Unify Communications and Develop Collaboration between 20,000 Users for JTI
Business Wire - Mon Mar 31, 3:00AM CDT
Orange Business Services has been chosen by JTI (Japan Tobacco International) to transform its digital working environment by moving its existing communications landscape to a fully managed unified communications solution based on Microsoft Lync(R) 2013.
Analyzing the Global Tobacco Industry 2014
M2 - Thu Mar 27, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ncfrq/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Major players in the industry are analyzed through a company overview, business segment analysis, financial analysis, and a SWOT analysis. With tobacco being one of the most commonly used addictive substances in the world, the industry will continue to grow in the coming years, though the growth is going to be faced with many challenges as countries put in place stringent laws to combat the health effects of consuming tobacco. Aruvians Rsearch's analysis of the global tobacco industry is a comprehensive analysis of the industry. Companies Mentioned - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor Visit http://www.researchandmarkets.com/research/4n...lyzing_the
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"
, today announced its financial results for the fourth quarter and year ended December 31, 2013. Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
